Among cognitively unimpaired participants with a family history of dementia, changes in cognition and brain MRI outcomes from baseline to year 3 did not differ significantly between those who followed the MIND diet and those who followed the control diet with mild caloric restriction. 5 key findings →
Design: RCT
Participants: 604
Evidence: null result
Full summary, score breakdown and related studies →
Original source
Free full text
83/100
✓ Peer-reviewed
alzhub usefulness score 83 out of 100.
·
JAMA Neurology
·
2025-05-01
ARIA is an adverse event associated with donanemab treatment that requires safety monitoring. 4 key findings →
Design: phase-3-trial
Participants: 3,030
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
Tau accumulation in patients with Alzheimer's disease tracks closely with cognitive decline and plays a role in the later stages of disease progression. 4 key findings →
Design: clinical trial
Participants: 108
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
81/100
✓ Peer-reviewed
alzhub usefulness score 81 out of 100.
·
JAMA neurology
·
2022-11-01
There were 813 participants in CREAD (mean [SD] age, 70.7 [8.2] years; 483 female and 330 male) and 806 in CREAD2 (mean [SD] age, 70.9 [7.7] years; 456 female and 350 male). 2 key findings →
Design: clinical trial
Participants: 3,664
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
81/100
✓ Peer-reviewed
alzhub usefulness score 81 out of 100.
·
Gastroenterology
·
2019-05-29
In a large placebo-controlled randomized trial, we found that pantoprazole is not associated with any adverse event when used for 3 years, with the possible exception of an increased risk of enteric infections. 5 key findings →
Design: randomized controlled trial
Participants: 8,791
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
Enrollment was undertaken between May 18, 2021, and September 8, 2023. 2 key findings →
Design: clinical trial
Participants: 210
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
80/100
✓ Peer-reviewed
alzhub usefulness score 80 out of 100.
·
JAMA
·
2013-10-01
During the CEE plus MPA intervention phase, the numbers of CHD cases were 196 for CEE plus MPA vs 159 for placebo (hazard ratio [HR], 1.18; 95% CI, 0.95-1.45) and 206 vs 155, respectively, for invasive breast cancer (HR, 1.24; 95% CI, 1.01-1.53). 3 key findings →
Participants: 8,506
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
Overall, 1795 participants from Core and 1612 participants with at least one dose of lecanemab (Core + OLE) were included. 1 key finding →
Design: open-label trial
Participants: 1,795
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
78/100
✓ Peer-reviewed
alzhub usefulness score 78 out of 100.
·
JAMA
·
2018-01-01
Dose group efficacy required a significant benefit over placebo for the primary end point and 1 or more key secondary end points. 4 key findings →
Participants: 933
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
Gradual up-titration of dose significantly reduced ARIA-E risk while demonstrating comparable pharmacokinetics/pharmacodynamics compared to standard dosing. 5 key findings →
Design: phase-3-trial
Participants: 843
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
75/100
✓ Peer-reviewed
alzhub usefulness score 75 out of 100.
·
JAMA
·
2025-08-01
Among older adults at risk of cognitive decline and dementia, a structured, higher-intensity intervention had a statistically significant greater benefit on global cognition compared with an unstructured, self-guided intervention. 5 key findings →
Participants: 1,056
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
In a large cohort of cognitively unimpaired individuals enrolled in a Phase 3 clinical trial and companion observational study, these findings confirm that higher baseline levels of amyloid and tau markers are associated with increased rates of cognitive decline and progression to functional impairment. 5 key findings →
Design: longitudinal study
Participants: 583
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
74/100
✓ Peer-reviewed
alzhub usefulness score 74 out of 100.
·
JAMA neurology
·
2024-06-01
Of 236 eligible participants screened, 43 were excluded. 2 key findings →
Design: longitudinal study
Participants: 142
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
Fifty-one AD patients enrolled, mean age 73.5. 4 key findings →
Design: clinical trial
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
Delirium (or acute confusional state) affects 35% to 65% of patients after hip-fracture repair, and has been independently associated with poor functional recovery. 4 key findings →
Design: randomized controlled trial
Participants: 62
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
73/100
✓ Peer-reviewed
alzhub usefulness score 73 out of 100.
·
JAMA
·
2015-08-01
Among older persons with AMD, oral supplementation with LCPUFAs or lutein/zeaxanthin had no statistically significant effect on cognitive function. 5 key findings →
Participants: 89
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
72/100
✓ Peer-reviewed
alzhub usefulness score 72 out of 100.
·
JAMA network open
·
2023-09-05
Goals-of-care documentation during the intervention phase occurred among 3744 of 6023 patients (62.2%) compared with 2396 of 4779 patients (50.1%) in the usual care phase (P Conclusions and relevance In this stepped-wedge cluster randomized clinical trial of older adults, a GOC video intervention delivered by PCEs resulted in higher rates of GOC documentation compared with usual care, including among Black or African American individuals, Hispanic or Latino individuals, non-English speakers, and people living with Alzheimer disease and related dementias. 3 key findings →
Participants: 802
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
72/100
✓ Peer-reviewed
alzhub usefulness score 72 out of 100.
·
JAMA psychiatry
·
2019-01-01
The study enrolled 181 participants (mean [SD] age, 69.6 [7.2] years; 114 [63.0%] female): 91 to the intervention arm (depression in later life [DIL] intervention) and 90 to care as usual (CAU). 1 key finding →
Participants: 181
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
These findings suggest medication-specific educational mailings targeting patients with AD or ADRD and their clinicians are not effective in reducing the use of high-risk medications. 4 key findings →
Design: open-label trial
Participants: 787
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
70/100
✓ Peer-reviewed
alzhub usefulness score 70 out of 100.
·
JAMA network open
·
2024-08-01
In this 3-year randomized clinical trial, ω-3 treatment was safe and well-tolerated but failed to reach significant reductions in WML accumulation or neuronal integrity breakdown among all participants, which may be attributable to sample size limitations. 5 key findings →
Participants: 102
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
69/100
✓ Peer-reviewed
alzhub usefulness score 69 out of 100.
·
JAMA Network Open
·
2025-03-03
The MBI component significantly improved multiple caregiver outcomes, with reduced depressive symptoms (β = -2.13 [95% CI, -2.85 to -1.38]; P Conclusions and relevance In this clinical trial of informal caregivers of people with dementia, synergistic interaction effects were noted for MBI, which enhanced the benefits of SC and BPM on depression. 2 key findings →
Design: RCT
Participants: 250
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
In male physicians aged 65 years or older, long-term use of a daily multivitamin did not provide cognitive benefits. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
PurposeTelephone disclosure of genetic test results can improve access to services. 4 key findings →
Participants: 257
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
68/100
✓ Peer-reviewed
alzhub usefulness score 68 out of 100.
·
Neurology
·
2018-02-02
Baseline biomarkers largely do not predict risk for developing ARIA-E. ARIA-E was associated with significant longitudinal changes in several biomarkers, with larger reductions in amyloid PET and CSF p-tau and t-tau concentrations, and paradoxically greater hippocampal volume reduction and ventricular enlargement, suggesting that ARIA-E in bapineuzumab-treated cases may be related to increased Aβ efflux from the brain and affecting downstream pathogenic processes. 4 key findings →
Design: longitudinal study
Participants: 1,512
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
68/100
✓ Peer-reviewed
alzhub usefulness score 68 out of 100.
·
Neurology
·
2012-10-24
Association of HT use and risk of AD may depend on timing of use. 4 key findings →
Design: randomized controlled trial
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor,
and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a
scientist can tell a landmark trial from a conference abstract without having to already know the
difference. Every point comes from one of 20 components, all of them printed on the study itself,
so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomized / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multicenter collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we
could not verify current impact factors from a source we control, and an invented one would be
worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science,
Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed
journal. A separate part scores how much the journal's own papers are cited, which tells the
tier-3 journals apart.
Two rules we don't bend. First, we never fill in a
missing value: if a record does not state a sample size or a design, that component scores
zero, and if we simply have no data for a part, such as a citation count, that part is left out and
the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed
article is capped at 16/100 and carries a warning chip — so a conference abstract or
a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not
work — above an early positive finding. Someone deciding whether to buy a supplement is served by
that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is
reproducible: the same file always yields the same numbers.
See the whole rubric drawn out →
— four charts covering all 32,980 studies: how the scores are spread and where the cap
bites, which of the 20 components the library is strong and weak on, which subjects rest on
stronger evidence, and what kinds of study each subject is actually built from.